Preprint Review Version 1 This version is not peer-reviewed

The Controversial Role of Ubiquitin-Conjugatin Enzyme E2 O (UBE2O) in Human Leukemias and Solid Tumors

Version 1 : Received: 10 July 2024 / Approved: 11 July 2024 / Online: 11 July 2024 (04:52:20 CEST)

How to cite: Maffeo, B.; Cilloni, D. The Controversial Role of Ubiquitin-Conjugatin Enzyme E2 O (UBE2O) in Human Leukemias and Solid Tumors. Preprints 2024, 2024070916. https://doi.org/10.20944/preprints202407.0916.v1 Maffeo, B.; Cilloni, D. The Controversial Role of Ubiquitin-Conjugatin Enzyme E2 O (UBE2O) in Human Leukemias and Solid Tumors. Preprints 2024, 2024070916. https://doi.org/10.20944/preprints202407.0916.v1

Abstract

Protein degradation is a biological phenomena essential for cellular homeostasis and survivor. Selective protein degradation is performed by the ubiquitination system which selectively target proteins that need to be eliminated and lead them to proteasome degradation. In this review, we focus on the ubiquitin-conjugating enzyme E2 O (UBE2O) and highlight the role of UBE2O in many biological and physiological process. We further discuss the UBE2O implications in various human diseases, particularly in leukemias and solid cancers and suggest how UBE2O targeting could be novel strategy in the treatment of different human neoplasia.

Keywords

UBE2O; UPS; ubiquitin; protein degradation; erythropoiesis; leukemia; solid tumors

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.